Section Arrow
ALZN.NASDAQ
- Alzamend Neuro Inc.
Quotes are at least 15-min delayed:2025/07/20 16:50 EDT
Regular Hours
Last
 3.28
-0.14 (-4.09%)
Day High 
3.485 
Prev. Close
3.42 
1-M High
3.5996 
Volume 
203.34K 
Bid
3.3
Ask
3.38
Day Low
3.24 
Open
3.41 
1-M Low
2.75 
Market Cap 
2.74M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.14 
20-SMA 3.04 
50-SMA 3.55 
52-W High 135.54 
52-W Low 2.75 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1,210.59/-15.21
Enterprise Value
2.74M
Balance Sheet
Book Value Per Share
4.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 16:50 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to developand market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.